Literature DB >> 26392073

Breast Cancer Tumor Suppressors: A Special Emphasis on Novel Protein Nischarin.

Mazvita Maziveyi1, Suresh K Alahari2.   

Abstract

Tumor suppressor genes regulate cell growth and prevent spontaneous proliferation that could lead to aberrant tissue function. Deletions and mutations of these genes typically lead to progression through the cell-cycle checkpoints, as well as increased cell migration. Studies of these proteins are important as they may provide potential treatments for breast cancers. In this review, we discuss a comprehensive overview on Nischarin, a novel protein discovered by our laboratory. Nischarin, or imidazoline receptor antisera-selected protein, is a protein involved in a vast number of cellular processes, including neuronal protection and hypotension. The NISCH promoter experiences hypermethylation in several cancers, whereas some highly aggressive breast cancer cells exhibit genomic loss of the NISCH locus. Furthermore, we discuss data illustrating a novel role of Nischarin as a tumor suppressor in breast cancer. Analysis of this new paradigm may shed light on various clinical questions. Finally, the therapeutic potential of Nischarin is discussed. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392073     DOI: 10.1158/0008-5472.CAN-15-1395

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase.

Authors:  Shengli Dong; Somesh Baranwal; Anapatricia Garcia; Silvia J Serrano-Gomez; Steven Eastlack; Tomoo Iwakuma; Donald Mercante; Franck Mauvais-Jarvis; Suresh K Alahari
Journal:  J Biol Chem       Date:  2017-08-24       Impact factor: 5.157

2.  Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and Tumor Growth.

Authors:  Mazvita Maziveyi; Shengli Dong; Somesh Baranwal; Ali Mehrnezhad; Rajamani Rathinam; Thomas M Huckaba; Donald E Mercante; Kidong Park; Suresh K Alahari
Journal:  Cancer Res       Date:  2019-01-11       Impact factor: 12.701

Review 3.  Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.

Authors:  Sadegh Rajabi; Catherine Alix-Panabières; Arshia Sharbatdar Alaei; Raziyeh Abooshahab; Heewa Shakib; Mohammad Reza Ashrafi
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 4.  Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.

Authors:  Samuel C Okpechi; Hassan Yousefi; Khoa Nguyen; Thomas Cheng; Nikhilesh V Alahari; Bridgette Collins-Burow; Matthew E Burow; Suresh K Alahari
Journal:  Oncogene       Date:  2022-01-22       Impact factor: 9.867

Review 5.  Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer.

Authors:  Isela Martínez-Reza; Lorenza Díaz; Rocío García-Becerra
Journal:  J Biomed Sci       Date:  2017-12-04       Impact factor: 8.410

6.  Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.

Authors:  Xianneng Sheng; Yu Guo; Yang Lu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 7.  Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.

Authors:  Meng Ye; Tao Huang; Ying Ying; Jinyun Li; Ping Yang; Chao Ni; Chongchang Zhou; Si Chen
Journal:  Oncotarget       Date:  2017-02-07

8.  Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).

Authors:  Zipei Cao; Lijuan Wei; Weizhi Zhu; Xuping Yao
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

9.  Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer.

Authors:  Chunyan Shen; Qifang Sheng; Xiaojie Zhang; Yuling Fu; Kemiao Zhu
Journal:  J Ovarian Res       Date:  2016-09-26       Impact factor: 4.234

Review 10.  Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.

Authors:  Yu Zheng; Xia Li; Yiming Jiang; Yufen Xu; Binbin Song; Qiang Zhou; Xiaodong Liang; Xinmei Yang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.